Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris reports robust 2022 performance, eyes growth through strategic initiatives

Viatris showcased strong financial performance and strategic execution in 2022, with a focus on integration and debt reduction post-merger.
The company's emphasis on capital allocation, product launches, and market expansion highlights a balanced approach to growth and shareholder returns.
Challenges lie in effective debt management, successful product launches, and balancing R&D investments with capital returns for optimal growth.
Overall, Viatris remains poised for growth with opportunities in new product launches, market expansion, and revenue diversification in 2023.

Viatris reports robust Q1 earnings, eyes growth in key markets

Viatris delivered strong Q1 financial performance, reaffirmed 2023 guidance, and expressed confidence in strategic plan execution.
The company's focus on key therapeutic areas, successful acquisitions, and product developments position it for growth.
While facing challenges in base business erosion and market dynamics, Viatris is exploring opportunities in new products and strategic acquisitions for future growth.

Viatris reports robust Q2 earnings, eyes strategic divestitures for growth

Viatris (VTRS) had a strong Q2 2023, reaffirming guidance, showcasing revenue growth in key markets, and addressing analyst inquiries on tax structures and market impacts. The company's focus on strategic divestitures and therapeutic verticals presents growth opportunities amidst challenges in pricing and market dynamics.

Viatris reports robust Q3 results, navigates challenges for future growth

Viatris' Q3 performance reflects strong operational results, strategic divestitures, and a focus on shareholder value creation amidst challenges from FX and inflation.
The company's financial resilience, commitment to growth, and effective cost management underscore its ability to navigate market dynamics and drive long-term success.
With a solid foundation in place, Viatris remains well-positioned to capitalize on growth opportunities, drive innovation, and deliver value to shareholders.

Viatris reports strong 2023 performance and eyes transformational 2024

Viatris had a strong 2023 and anticipates a transformational 2024 with strategic investments and capital return to shareholders.
The company's collaboration with Idorsia for exclusive global rights to assets offers significant revenue growth potential and pipeline expansion.
Despite challenges like portfolio rationalization and FTC inquiry impact, Viatris is optimistic about future growth and product launches.

Viatris reports robust Q1 performance and charts growth opportunities

Viatris delivered strong financial performance, reaffirmed guidance, and introduced new revenue projections, showcasing stability and growth potential.
While facing divestiture challenges, the company's strategic initiatives, leadership additions, and pipeline progress position it for future success.
Opportunities for revenue growth, shareholder value enhancement, and innovation highlight Viatris' path towards sustained growth and market leadership.

Viatris excels in Q3 earnings, eyes growth through innovation

Viatris demonstrated strong financial performance in Q3 2024, showcasing revenue growth, debt repayment, and strategic investments. While facing challenges in Q4, the company remains committed to enhancing shareholder value and driving innovation. By leveraging its strengths and addressing key challenges, Viatris aims to seize growth opportunities and deliver long-term value to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coterra Energy

Skechers U.S.A.

The momentum in technology stocks has buoyed the markets to new highs, leaving investors in a dilemma. Do they chase the hot AI and technology that have outperformed or stick with bargain stocks?

3 Bargain Stocks to Snatch Up Before They Bounce Back

Viatris' (VTRS) Q4 results are likely to gain from momentum in its branded and generic businesses.

Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?

Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Insights Into Viatris (VTRS) Q4: Wall Street Projections for Key Metrics

PITTSBURGH , Feb. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will announce its fourth quarter and full-year 2023 financial results Wednesday, Feb. 28, 2024, before the open of the U.S. financial markets. Chief Executive Officer  Scott A.

Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results

Amgen

Centene

Cencora Inc

Catalent

Gilead Sciences

Medtronic

Merck

Moderna

Regeneron Pharmaceuticals

The sector has seen one of the best starts to the year in decades, Goldman says.

10 Healthcare Stocks That Are Heating Up

Health Care Select Sector SPDR Fund

AbbVie

Danaher

DexCom

Eli Lilly

McKesson

UnitedHealth Group

Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts have cited attractive valuations relative to earnings and a compelling growth story as two reasons health-care stocks might continue to outperform.

Charts turn bullish on health-care stocks as sector takes early lead in 2024

Allstate

Arista Networks

Intuitive Surgical

NVIDIA

Palo Alto Networks

The S&P 500 rebounded last week near record highs, but is up just 0.2% so far in 2024. These are the index's top performers so far.

These 9 Stocks Are Running To Start 2024

Viatris is an American pharmaceutical company formed as a result of the merger of Mylan and Upjohn. Over the past two and a half months, Viatris' share price has risen by more than 38%. Viatris' dividend yield is 3.97%, which is attractive because it is well above the sector median.

From Euphoria To Reality: Viatris' Tale Of Market Whirlwind

Viatris Inc. (VTRS) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

Incyte

The calendar just flipped to 2024 — and investors already have their favorite S&P 500 stocks. And none of them are the Big Tech giants that dominated.

7 Stocks Are Taking Off Already — And The Year Just Started

PITTSBURGH , Dec. 21, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024.

Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Global healthcare company Viatris on Friday appointed Theodora Mistras as its chief financial officer, effective March 1.

Drugmaker Viatris appoints Theodora Mistras as CFO

Company thanks Sanjeev Narula for his role in the successful execution of Viatris' Phase 1 strategy; Narula will support a smooth CFO transition prior to his departure on March 1, 2024 PITTSBURGH , Dec. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that, as it prepares to enter Phase 2 of its strategic plan, Theodora "Doretta" Mistras has been appointed Chief Financial Officer (CFO) effective March 1, 2024, and Philippe Martin has been appointed Chief R&D Officer with immediate effect. Current Viatris CFO Sanjeev Narula, who helped the company successfully execute its Phase 1 strategy, will work closely with Mistras to support a smooth transition and will then depart the company on March 1, 2024.

Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer

Board of Directors Elects Melina Higgins New Chair PITTSBURGH , Dec. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced that at its 2023 Annual Meeting of Shareholders held today, shareholders voted to re-elect all nominated Directors and approved/ratified all voting matters. The official voting results for each item voted on by shareholders will be disclosed in a current report on Form 8-K to be filed with the Securities and Exchange Commission.

Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?

Viatris (VTRS) Up 5.1% Since Last Earnings Report: Can It Continue?

General Motors

Ford Motor Company

Hewlett Packard

Kraft Heinz

Mohawk Industries

Mosaic

Paramount Global

Tyson Foods

Walgreens

Warner Bros Discovery Inc

It's no secret famed investor Warren Buffett sold off all his General Motor stock. But it's just one S&P 500 stock that worth more dead than alive.

11 Beat-Up Big Stocks (Like GM) Are Worth More Dead Than Alive

BENGALURU, India, Nov. 30, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris' biosimilars business in 31 European countries has been successfully completed. Following the acquisition of substantially all of the global biosimilar business of Viatris in November 2022 , and the related integration of over 70 emerging market countries in July 2023  and North America in September 2023 , the full transition of Viatris' biosimilars operations to Biocon Biologics Ltd in Europe represents another significant milestone as a world-leading biosimilars company.

Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe

Viatris shares had a negative 25% total return in the past 2 years, underperforming the S&P 500. The decline is likely due to the company's debt burden and stagnant revenues. Despite this, now may be a good time to consider buying VTRS as its valuation is low and there are signs of future improvement in financial performance.

Viatris Stock Is Dirt Cheap And Worth Buying

ACCO Brands

BuildABear

Boyd Gaming

Livent Corp

TEGNA

Tapestry

Screening for stocks with low price-to-earnings ratios is a great place to start when looking for value stocks, but your search for low P/E value stocks should not end there. That is, it's not as if you can screen for the stocks with the lowest P/E ratios, purchase them, and expect to generate outsized returns.

7 Low P/E Stocks Poised to Rebound

Viatris is the old generic drug company Mylan, acquired by Pfizer and merged with its Upjohn division. The stock has been falling ever since the deal closed.

Why the Cheapest Stock in the S&P 500 Is No Bargain

PITTSBURGH , Nov. 14, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jefferies London Healthcare Conference in London, UK on Wednesday, November 15, 2023. Chief Executive Officer Scott A.

Viatris to Participate in the Jefferies London Healthcare Conference

Theravance Biopharma

Top-line results from Phase III study in China demonstrate the efficacy and safety profile of YUPELRI in patients with COPD PITTSBURGH and DUBLIN , Nov. 13, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced positive results from the YUPELRI® (revefenacin) Phase III placebo-controlled clinical trial conducted in China assessing the efficacy and safety of YUPELRI, a once-daily nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of patients with COPD. Top-line results showed that YUPELRI met its primary efficacy endpoint demonstrating a statistically significant increase in trough FEV1 (forced expiratory volume in one second) versus placebo.

Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say

Viatris (VTRS) third-quarter earnings beat estimates. While brands maintain business, the Complex generics business performs below management's expectations.

Viatris (VTRS) Q3 Earnings Beat, Complex Generics Sales Dip

Viatris Inc. (NASDAQ:VTRS ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants William Szablewski - Head of Global Capital Markets Scott Smith - CEO Rajiv Malik - President Sanjeev Narula - CFO David Bayles - Chief Compliance Officer Brian Roman - Global General Counsel Conference Call Participants Christopher Schott - JPMorgan Nathan Rich - Goldman Sachs Umer Raffat - Evercore ISI Glenn Santangelo - Jefferies Jason Gerberry - Bank of America Ash Verma - UBS David Amsellem - Piper Sandler Operator Hello. My name is Travis, and I will be your conference operator today.

News for Viatris Stock (VTRS)